Azenta, Inc. (AZTA) Revenue by Segment & Business Profile
Multiomics was 45.2% of Azenta, Inc.'s revenue across the 3 lines it reports, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AZTAAzenta, Inc.Follow AZTA — free
—
Price chart with a free account
- Market cap
- 1.6B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 17 Nov, in 24 days
What the company does
Azenta, Inc. is a medical instruments & supplies company in the healthcare sector. In its SEC filings it reports 3 business lines: Multiomics (45%), Core Products (30%), Sample Repository Solutions (25%). Trailing twelve-month revenue: $613.8 million as of 2026-06-30.
Roles we read
from the filings, not the sector label- Lab / biopharma supplies
Revenue by geography
latest quarter · company segment note| Region | Revenue | Share | y/y |
|---|---|---|---|
| United States | 92M | 56.8% | +4.2% |
| Europe | 30M | 18.6% | +17.9% |
| China | 19M | 11.7% | +31.2% |
| United Kingdom | 12M | 7.5% | +30.1% |
| Asia Pacific Excluding China | 7M | 4.3% | +19.8% |
| Other | 2M | 1.2% | +53.9% |
Azenta, Inc. — questions
- What does Azenta, Inc. do?
- Azenta, Inc. is a medical instruments & supplies company in the healthcare sector. In its SEC filings it reports 3 business lines: Multiomics (45%), Core Products (30%), Sample Repository Solutions (25%). Trailing twelve-month revenue: $613.8 million as of 2026-06-30.
- How does Azenta, Inc. make money?
- By the lines it reports in its SEC filings: Multiomics 45.2%, Core Products 29.6%, Sample Repository Solutions 25.2% of revenue.
Every figure on this page comes from Azenta, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.